Figure 3. Knock-down of MuRF2 decreased skeletal muscle fibroblast wound healing capacity. Phase contrast microscope image from skeletal muscle fibroblasts in wound healing assay at different time points (2, 4, 6, and 24 h). Skeletal muscle fibroblasts treated with scrambled (SCRBd) (A, C, E, and G) and with MuRF2 siRNA (B, D, F, and H); I: Percentage of wound closure obtained from the phase contrast microscope. Ki67-positive nuclei in skeletal muscle fibroblasts submitted to wound healing assay at 2, 4, 6 and 24 h (J–Q). Skeletal muscle fibroblasts treated with SCRBd (J, L, N, and P) and with MuRF2 siRNA (K, M, O, and Q). R: Percentage of Ki67-positive cells. Data are reported as means±SE. *P<0.05 vs SCRBd (t-test). Scale bar, 100 µM.
